Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LCTX
stocks logo

LCTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.96M
-31.67%
-0.047
+371.4%
1.77M
+18.12%
-0.022
+10%
6.57M
+137.76%
-0.010
-92.31%
Estimates Revision
The market is revising No Change the revenue expectations for Lineage Cell Therapeutics, Inc. (LCTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.62%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+42.62%
In Past 3 Month
Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 5.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 5.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.740
sliders
Low
3.00
Averages
5.00
High
9.00
Current: 1.740
sliders
Low
3.00
Averages
5.00
High
9.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$9
2025-11-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-11-24
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $9 price target on Lineage Cell Therapeutics (LCTX), saying the major breakout event the firm is looking for is visibility out of global partner Roche (RHHBY) regarding OpRegen data and next steps. Monday's $5M milestone represents yet another tangible piece of evidence for Roche's progress in the OpRegen program for which they have global rights for dry-AMD and geographic atrophy, the analyst tells investors in a research note. The firm added that data, anecdotes, and comps provide significant support that OpRegen is moving into later studies in Roche's hands.
B. Riley Securities
Mayank Mamtani
Strong Buy
Maintains
$4 → $3
2025-03-14
Reason
B. Riley Securities
Mayank Mamtani
Price Target
$4 → $3
2025-03-14
Maintains
Strong Buy
Reason
B. Riley analyst Mayank Mamtani lowered the firm's price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the shares. Lineage Cell Therapeutics' Q4 recap focused on Roche (RHHBY)-partnered OpRegen program, steadily advancing earlier-stage wholly-owned programs, and Lineage's dominant position in large-scale allogeneic manufacturing to produce millions of retinal pigment epithelium cells, the analyst tells investors in a research note. The OpRegen dry AMD opportunity could come through the ongoing Phase II GAlette study interim data release, and Roche opting to progress to a randomized controlled study to confirm high efficacy benefits noted with optimized delivery system in sizeable patient population, the firm says.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$9
2025-03-11
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$9
2025-03-11
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$2
2025-03-11
Reason
D. Boral Capital
Jason Kolbert
Price Target
$2
2025-03-11
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$3 → $2
2025-02-11
Reason
D. Boral Capital
Jason Kolbert
Price Target
$3 → $2
2025-02-11
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$9
2025-01-31
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$9
2025-01-31
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lineage Cell Therapeutics Inc (LCTX.A) is -17.21, compared to its 5-year average forward P/E of -9.75. For a more detailed relative valuation and DCF analysis to assess Lineage Cell Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.75
Current PE
-17.21
Overvalued PE
-5.80
Undervalued PE
-13.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-13.80
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.25
Undervalued EV/EBITDA
-39.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
42.77
Current PS
0.00
Overvalued PS
92.82
Undervalued PS
-7.29
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 9203.77% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 9203.77% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LCTX News & Events

Events Timeline

(ET)
2025-11-24
12:18:39
Lineage Cell announces achievement of initial OpRegen development milestone in collaboration with Roche
select
2025-11-06 (ET)
2025-11-06
16:08:02
Lineage Cell Therapeutics Announces Q3 Earnings Per Share of 13 Cents, Exceeding Consensus of 3 Cents
select
2025-09-08 (ET)
2025-09-08
08:09:27
Lineage Cell Therapeutics Launches New Program for Islet Cell Transplants
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-04Benzinga
Snowflake, Symbotic, and Other Major Stocks Decline in Thursday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures up by approximately 0.1% on Thursday morning.

  • Snowflake Inc Performance: Snowflake Inc reported third-quarter revenue of $1.21 billion, surpassing analyst expectations, but its shares fell 8.6% in pre-market trading.

  • Other Stocks Declining: Several other stocks experienced significant declines in pre-market trading, including Net Lease Office Properties down 14.7% and Symbotic Inc down 10.5% following a share offering announcement.

  • Additional Stock Movements: Other notable declines included Capricor Therapeutics down 8.4% after a previous surge, and ADC Therapeutics down 8.1% after reporting trial data.

[object Object]
Preview
1.0
09-13Newsfilter
Lineage Cell Therapeutics, Inc. (LCTX) Shares Prepared Remarks at H.C. Wainwright's 27th Annual Global Investment Conference

  • Company Overview: Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing novel cell therapies for neurological and ophthalmic conditions, particularly targeting diseases caused by the loss of specific cell types.

  • Key Focus Area: The company is currently concentrating on treating dry age-related macular degeneration by manufacturing and delivering retinal pigment epithelium (RPE) cells to restore lost function in affected patients.

[object Object]
Preview
7.5
08-26Newsfilter
Lineage Partners with William Demant Invest to Advance ReSonance™ (ANP1) for Hearing Loss Research

  • Collaboration Announcement: Lineage Cell Therapeutics has partnered with William Demant Invest to advance the preclinical development of its auditory neuronal cell transplant, ReSonance (ANP1), aimed at treating hearing loss.

  • Funding Details: William Demant Invest will contribute up to $12 million for research collaboration costs, which will support various preclinical activities including cell manufacturing and regulatory strategy.

  • Significance of Hearing Loss: The World Health Organization predicts that nearly 2.5 billion people will experience some degree of hearing loss by 2025, highlighting the urgent need for effective treatments like cell-based therapy.

  • Company Backgrounds: Lineage Cell Therapeutics focuses on developing novel cell therapies for unmet medical needs, while William Demant Invest is an evergreen investor linked to a leading hearing healthcare company, emphasizing their commitment to advancing hearing health solutions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lineage Cell Therapeutics Inc (LCTX) stock price today?

The current price of LCTX is 1.74 USD — it has increased 3.57 % in the last trading day.

arrow icon

What is Lineage Cell Therapeutics Inc (LCTX)'s business?

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

arrow icon

What is the price predicton of LCTX Stock?

Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 5.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lineage Cell Therapeutics Inc (LCTX)'s revenue for the last quarter?

Lineage Cell Therapeutics Inc revenue for the last quarter amounts to 3.68M USD, decreased -2.59 % YoY.

arrow icon

What is Lineage Cell Therapeutics Inc (LCTX)'s earnings per share (EPS) for the last quarter?

Lineage Cell Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, increased 550.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lineage Cell Therapeutics Inc (LCTX)'s fundamentals?

The market is revising No Change the revenue expectations for Lineage Cell Therapeutics, Inc. (LCTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.62%.
arrow icon

How many employees does Lineage Cell Therapeutics Inc (LCTX). have?

Lineage Cell Therapeutics Inc (LCTX) has 70 emplpoyees as of December 05 2025.

arrow icon

What is Lineage Cell Therapeutics Inc (LCTX) market cap?

Today LCTX has the market capitalization of 401.92M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free